Navigation Links
NuVasive Acquires First Stem Cell Bone Graft Substitute
Date:5/14/2008

New technologies will drive US bone graft substitute market to reach almost

$1.9 billion by 2012, according to Millennium Research Group

WALTHAM, Mass., May 14 /PRNewswire/ -- With the acquisition of Osiris Therapeutics' Osteocel business, NuVasive has obtained the first off-the-shelf bone graft substitute (BGS) product to incorporate viable stem cells. Mounting surgeon excitement about this new BGS and other innovative products will drive the BGS market to $1.9 billion in 2012, according to Millennium Research Group's US Markets for Orthopedic Biomaterials 2008 report.

"The popularity of advanced BGS technologies has increased competition within the field. Medtronic Spinal and Biologics' INFUSE BGS, based on a recombinant human bone morphogenetic protein, has forced NuVasive and other BGS competitors to dramatically innovate," says Kevin Flewwelling, Orthopedics Research Manager at Millennium Research Group. "In 2007, INFUSE sales exceeded $700 million in the US and NuVasive saw an opportunity to compete against this very successful product."

In order to compete against these advanced BGS, other manufacturers of traditional BGS products -- such as demineralized bone matrices and synthetics -- are developing next-generation products that offer improved ease-of-use and superior bone healing and regrowth. Companies claim that these new features eliminate the need for autograft bone harvested from the patient's iliac crest, reducing postoperative pain and morbidity at the donor site. With these greater advantages, surgeons are shifting towards these newer devices. A survey of surgeons conducted by Millennium Research Group found that 30.3% expected to perform fewer procedures using only autograft bone by 2012.

In addition to the BGS market, the US Markets for Orthopedic Biomaterials 2008 report covers the hyaluronic acid viscosupplementation, machined bone interbody device, knee cartilage repair, and cell concentration system markets. The report also provides coverage of all key industry competitors, including AlloSource, Biomet, Blackstone Medical/Orthofix, DePuy, Exactech, Ferring Pharmaceuticals, Genzyme Biosurgery, Integra LifeSciences/IsoTis, LifeNet Health, Medtronic Spinal and Biologics, Musculoskeletal Transplant Foundation, Orthovita, Osiris Therapeutics, Osteotech, RTI Biologics, sanofi-aventis, Smith & Nephew, Stryker, Synthes, and Wright Medical Technology. Other reports in this series cover Europe (France, Germany, Italy, Spain, and the UK) and Japan.

About Bone Graft Substitutes

BGS are classified under the broader term of bone grafts. Bone grafts are used to promote bone healing and regrowth and fill bone voids in spinal fusion, trauma surgery, joint revision and reconstruction, and craniomaxillofacial surgery. These products can be classified into six categories: autograft, nonproprietary allograft, demineralized bone matrix, synthetics, growth factors -- such as bone morphogenetic proteins -- and stem cell products. Autograft is the only bone graft material that is taken from a patient's own body. Other bone graft materials are commonly referred to as BGS.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ThinkEquity Partners 5th Annual Growth Conference
2. NuVasive Announces Web Cast and Conference Call of Third Quarter 2007 Results
3. NuVasive Licenses Its Insert and Rotate Technology
4. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
5. NuVasive to Present at BIOCOM Investor Conference 2007
6. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
7. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
8. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
9. NuVasive Reports First Quarter 2008 Financial Results
10. Cogdell Spencer Inc. Acquires Summit Professional Plaza I and II in Brunswick, Georgia
11. Omnicom Acquires Leading Healthcare Marketing Communications Firm in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... California (PRWEB) , ... May 30, 2016 , ... ... easy to use inside of FCPX," said Christina Austin - CEO of Pixel ... exclusively for use within Final Cut Pro X. Choose from abstract transitions to ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy to announce ... been available via Amazon.com. This new style of nail clipper has a wider jaw ... is approximately 4mm and the actual handle is 2.5mm thick to accommodate the cutting ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can ... drop a preset onto their media," said Christina Austin - CEO of Pixel Film ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and professionals in ... lights on the variety of topics detailing why we appreciate nurses in so many ... career has gone from being in a major recession to one of the hottest ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology: